The store will not work correctly when cookies are disabled.
(E)-3-benzyl-2-(2-benzylidenehydrazinyl)-1,2-dihydroquinoxaline
ID: ALA4875623
PubChem CID: 164626796
Max Phase: Preclinical
Molecular Formula: C22H20N4
Molecular Weight: 340.43
Molecule Type: Unknown
Associated Items:
Names and Identifiers
Canonical SMILES: C(=N/NC1Nc2ccccc2N=C1Cc1ccccc1)\c1ccccc1
Standard InChI: InChI=1S/C22H20N4/c1-3-9-17(10-4-1)15-21-22(25-20-14-8-7-13-19(20)24-21)26-23-16-18-11-5-2-6-12-18/h1-14,16,22,25-26H,15H2/b23-16+
Standard InChI Key: CTUMCTXVWKPHLE-XQNSMLJCSA-N
Molfile:
RDKit 2D
26 29 0 0 0 0 0 0 0 0999 V2000
23.6329 -15.0006 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
23.6318 -15.8280 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
24.3466 -16.2409 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
24.3448 -14.5878 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
25.0603 -14.9970 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
25.0591 -15.8301 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
26.4999 -14.9990 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
25.7783 -14.5791 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
27.2154 -14.5883 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
27.9289 -15.0026 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
27.9214 -15.8268 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
28.6341 -16.2409 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
29.3506 -15.8301 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
29.3500 -15.0008 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
28.6367 -14.5903 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
26.4987 -15.8322 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
25.7815 -16.2460 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
27.2129 -16.2453 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
27.2122 -17.0703 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
27.9263 -17.4835 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
27.9256 -18.3085 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
27.2118 -18.7174 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
27.2108 -19.5416 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
27.9255 -19.9556 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
28.6427 -19.5392 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
28.6401 -18.7164 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1 2 2 0
2 3 1 0
3 6 2 0
5 4 2 0
4 1 1 0
5 6 1 0
5 8 1 0
6 17 1 0
16 7 1 0
7 8 2 0
7 9 1 0
9 10 1 0
10 11 2 0
11 12 1 0
12 13 2 0
13 14 1 0
14 15 2 0
15 10 1 0
16 17 1 0
16 18 1 0
18 19 1 0
19 20 2 0
20 21 1 0
21 22 2 0
22 23 1 0
23 24 2 0
24 25 1 0
25 26 2 0
26 21 1 0
M END
Associated Targets(Human)
Molecule Features
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
Drug Indications
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanisms of Action
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Calculated Properties
Molecular Weight: 340.43 | Molecular Weight (Monoisotopic): 340.1688 | AlogP: 4.38 | #Rotatable Bonds: 5 |
Polar Surface Area: 48.78 | Molecular Species: NEUTRAL | HBA: 4 | HBD: 2 |
#RO5 Violations: ┄ | HBA (Lipinski): 4 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): ┄ |
CX Acidic pKa: 11.91 | CX Basic pKa: 4.16 | CX LogP: 5.13 | CX LogD: 5.13 |
Aromatic Rings: 3 | Heavy Atoms: 26 | QED Weighted: 0.53 | Np Likeness Score: -0.41 |
References
1. Ayoup MS, Abu-Serie MM, Awad LF, Teleb M, Ragab HM, Amer A.. (2021) Halting colorectal cancer metastasis via novel dual nanomolar MMP-9/MAO-A quinoxaline-based inhibitors; design, synthesis, and evaluation., 222 [PMID:34116327] [10.1016/j.ejmech.2021.113558] |